M. Anthony Mills & Christopher Beach, RCP
During the 2016 campaign, Donald Trump vowed to rein in rising prescription drug costs, even suggesting that the government get directly involved in negotiating prices. After the recent nomination of pharmaceutical executive Alex Azar to lead the Department of Health and Human Services, the president’s critics are wondering whether the campaign rhetoric was all bark and no bite. While a near-consensus exists that drug prices are a problem, there’s less agreement about the cause, much less a solution.
Source: Real Clear Politics